Wednesday, May 13, 2026, San Antonio, Texas, 11:15 AM – 12:45 PM Central Time (12:15 PM – 1:45 PM Eastern Time)
Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates
A Complimentary NCPD Symposium Held During the 51st Annual ONS Congress
Program Schedule — Central Time
10:45 AM – 11:15 AM — Registration and Lunch
11:15 AM – 12:45 PM — Educational Meeting
Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000
Meeting Room
Grand Ballroom A-F (Third Floor)
Faculty Courtney Arn, CNP
The James Cancer Hospital and Solove Research Institute
The Ohio State University
Columbus, Ohio
Jamie Carroll, APRN, MSN, CNP
Assistant Professor, Oncology
Mayo Clinic
Rochester, Minnesota
Edward B Garon, MD, MS
Professor
Director, Thoracic Oncology Program
Director, Signal Transduction and Therapeutics Research Program
David Geffen School of Medicine at UCLA
Jonsson Comprehensive Cancer Center
Los Angeles, California
Heather McArthur, MD, MPH, FASCO
Professor, Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas
Moderator Kathleen N Moore, MD, MS
Deputy Director and Director, Phase 1 Clinical Trials
Fred and Pamela Buffett Cancer Center at the University of Nebraska
Omaha, Nebraska
Meeting space has been assigned to provide a symposium supported by AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Merck during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
10:45 AM – 11:15 AM — Registration and Lunch
11:15 AM – 12:45 PM — Educational Meeting
MODULE 1: Rationale for the Use of Antibody-Drug Conjugates (ADCs) as Cancer Treatment
Rationale for conjugating monoclonal antibodies with cytotoxic drugs to form ADCs; theoretical improvement of chemotherapy efficacy while reducing systemic exposure and toxicity
Structural components, such as antibodies, linkers and cytotoxic payloads, of commercially available and investigational ADCs
Direct mechanism of antitumor activity of ADCs and other means by which they can elicit an antitumor effect, such as bystander killing
MODULE 2: Current and Future Role of ADCs in Cancer Therapy
FDA-approved indications for ADCs in various tumor types
Clinical significance of FDA breakthrough therapy designation and current ADCs in development receiving this distinction
Biological rationale for combining ADCs with other cancer therapies (eg, immune checkpoint inhibitors) and current and future role of this strategy in treatment
Emerging findings with and ongoing studies evaluating ADCs for patients with non-metastatic disease
Other promising investigational ADCs in clinical development
MODULE 3: Practical Considerations with ADCs
Setting patient expectations regarding ADC efficacy and tolerability
Optimal timing for initiation of approved ADCs or consideration of a clinical trial evaluating 1 of these agents
ADC effectiveness for patients with CNS metastases
Mechanisms of resistance to ADCs; feasibility of using multiple agents in this class sequentially for the same patient
MODULE 4: Cytopenias Associated with ADCs
Educating patients regarding the capacity of ADCs to cause acute “chemotherapy-like” side effects
Incidence and severity of neutropenia, thrombocytopenia and anemia with approved and investigational ADCs
Indications for prophylactic growth factor use for patients who are about to start treatment with an ADC
Appropriate monitoring of complete blood counts during ADC therapy; thresholds for dose modification, treatment interruption and treatment discontinuation for patients experiencing cytopenias
MODULE 5: Gastrointestinal (GI) Adverse Events (AEs) Documented with ADCs
Rates of various GI issues (eg, nausea, vomiting, diarrhea, constipation, abdominal pain) in patients receiving ADC therapy
Indications for prophylactic antiemetics and antidiarrheals for patients who are about to start treatment with an ADC
Role of nutritional counselling and diet modifications during ADC treatment
Potential advantages of complementary therapies, such as acupuncture and yoga, in managing GI side effects of ADCs
MODULE 6: Recognition and Management of Interstitial Lung Disease (ILD)/Pneumonitis Associated with ADCs
Pathophysiology of ILD/pneumonitis associated with ADCs; baseline risk factors for its development
Rates, severity and timing of ILD/pneumonitis in clinical trial experiences with various ADCs
Appropriate workup for patients suspected of experiencing therapy-related ILD/pneumonitis; strategies to distinguish drug-related pulmonary toxicity from other potential causes
Guidelines for treatment modifications and discontinuation for patients experiencing ILD/pneumonitis; indications for restarting ADC therapy after resolution
Utility of other supportive care measures, such as corticosteroids and oxygen supplementation, for patients experiencing ILD/pneumonitis
MODULE 7: Potential for Mucositis/Stomatitis with ADCs
Incidence and severity of mucositis/stomatitis with various approved and investigational ADCs
Counseling patients on the importance of oral hygiene during treatment with ADCs known to cause mucositis/stomatitis
Role of steroid mouthwash, prophylactic antibiotics/antifungals and pain medications for patients who are at risk for or are experiencing mucositis/stomatitis
Dietary recommendations for patients experiencing mucositis/stomatitis
MODULE 8: Ocular Toxicities with ADCs
Pathophysiology of ocular AEs associated with certain ADCs; spectrum, incidence and severity of ocular toxicities with different agents
Optimal patient counseling and education regarding signs of ocular toxicity and the importance of early reporting of symptoms
Utility of other prophylactic and supportive care measures to mitigate and manage ocular toxicities
Importance of interdisciplinary coordination with eye-care professionals in the identification and management of treatment-related ocular AEs
MODULE 9: Cardiovascular AEs Associated with Select ADCs
Pathophysiology of the cardiotoxicity associated with anti-HER2 therapies, including ADCs
Incidence of left ventricular dysfunction noted with HER2-targeted ADCs in clinical trial experiences
Appropriate monitoring of left ventricular ejection fraction (LVEF) at baseline and during treatment with HER2-targeted ADCs
Threshold for treatment interruption for patients experiencing LVEF decrease; indications for restarting HER2-targeted ADC therapy after recovery
Role of interdisciplinary coordination with cardiologists when monitoring for and managing cardiac toxicities associated with HER2-targeted ADCs
MODULE 10: Other Toxicities Reported with ADCs
Incidence and management of peripheral neuropathy associated with various ADCs
Rates of alopecia reported with ADC treatment; available strategies to reduce the incidence/severity of hair loss or limit its psychosocial impact (eg, scalp-cooling methods, wigs/hair pieces)
Available strategies to ameliorate the symptoms of rash and other cutaneous reactions associated with ADCs (eg, antihistamines, topical steroids, emollients)
Spectrum of other toxicities (eg, fatigue, hemorrhage, effusion/edema, hyperglycemia) associated with 1 or more ADCs used in the treatment of cancer
Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
Consider the scientific justification for antibody-drug conjugates (ADCs) as a therapeutic approach for patients with various tumor types, and recall the differential targets, structural components and mechanisms of activity of different clinically available and investigational ADCs.
Appraise available clinical research data with novel ADCs for various cancers, and consider the current and potential role of these approaches in routine clinical care.
Appreciate the pathophysiology and severity of common and rare toxicities associated with ADCs employed in the treatment of different tumor types.
Understand the incidence of toxicities observed in pivotal trials evaluating novel ADCs demonstrating efficacy in the management of various tumor types, and educate patients about to commence therapy with these approaches regarding the potential development of adverse events and what to do if they are suspected.
Recall strategies commonly employed to identify, manage and mitigate toxicities resulting from anticancer treatment with ADCs, and use this information to appropriately intervene for patients in whom these side effects are suspected or diagnosed.
Understand the role of multidisciplinary specialists such as cardiologists, ophthalmologists and other medical professionals in the diagnosis and management of various ADC-associated toxicities, and effectively educate patients regarding the potential need for and importance of specialty referral.
Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.
Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY
— The following faculty reported relevant financial relationships with ineligible entities:
Ms Arn — Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genmab US Inc, GSK, Merck, Pfizer Inc.
Ms Carroll — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Lilly, Novartis.
Dr Garon — Consulting Agreements: AbbVie Inc, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Black Diamond Therapeutics Inc, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo Inc, Gilead Sciences Inc, GSK, Hexagon Bio, I-Mab Biopharma, IO Biotech, iTeos Therapeutics, LianBio, Merck, Novartis, Oxford BioTherapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Samsung Bioepis, Sanofi, Servier Pharmaceuticals LLC, Strata Oncology, Synthekine, TransCode Therapeutics, Verastem Inc; Contracted Research: ABL Bio, ArriVent Biopharma, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Iovance Biotherapeutics, Lilly, Merck, Novartis, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Synthekine, TILT Biotherapeutics; Data and Safety Monitoring Boards/Committees: Bicycle Therapeutics, Nuvalent, Servier Pharmaceuticals LLC.
Dr McArthur — Advisory Committees: Arvinas, AstraZeneca Pharmaceuticals LP, Boston Scientific Corporation, Celcuity, Daiichi Sankyo Inc, Delcath Systems Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc; Consulting Agreements: ALX Oncology.
RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Merck.
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000
Meeting Room
Grand Ballroom A-F (Third Floor)
Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.
No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.
NOTICE Registration for this event is independent of registration for the 2026 ONS Congress.
IN-PERSON registration for nurses and healthcare providers
I am a practicing nurse or healthcare provider involved in the care of patients with cancer.
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
